PURPOSE: BRCA1 and BRCA2 are considered to be breast cancer susceptibility genes that may also contribute to pancreatic cancer development because family studies revealed mutation carriers to have an increased risk of developing pancreatic cancer. However, as demonstrated for breast and ovarian cancer, inactivation of BRCA in sporadic diseases is based on alteration in gene expression or functional alteration. EXPERIMENTAL DESIGN: To study a potential correlation of BRCA1 and BRCA2 to chronic pancreatitis and development of sporadic pancreatic adenocarcinoma, we have analyzed the expression of these genes by quantitative PCR and performed immunohistochemical analyses in normal pancreatic tissues, chronic pancreatitis, and pancreatic cancer specimens. RESULTS: BRCA1 expression was down-regulated in chronic alcoholic pancreatitis, in particular on the RNA level. Furthermore, our data indicate suppressed BRCA1 expression in pancreatic cancer on both the RNA and protein levels. Quantitative analysis of BRCA1 protein expression demonstrated regular staining in 50% of tumor specimens tested and reduced staining in 50% of tumor specimens tested. Correlation with the clinical outcome revealed a significantly better 1-year overall survival for patients with BRCA1-regular as compared with BRCA1-reduced or BRCA1-absent tumors. In contrast, no substantial differences in BRCA2 expression were found in chronic pancreatitis and pancreatic cancer samples. CONCLUSIONS: Our data demonstrate alteration of BRCA1 expression in chronic pancreatitis and sporadic pancreatic adenocarcinoma. We, for the first time, provide evidence for a role of BRCA1 in pancreatic carcinogenesis of noninherited tumors and for clinical outcome.
PURPOSE:BRCA1 and BRCA2 are considered to be breast cancer susceptibility genes that may also contribute to pancreatic cancer development because family studies revealed mutation carriers to have an increased risk of developing pancreatic cancer. However, as demonstrated for breast and ovarian cancer, inactivation of BRCA in sporadic diseases is based on alteration in gene expression or functional alteration. EXPERIMENTAL DESIGN: To study a potential correlation of BRCA1 and BRCA2 to chronic pancreatitis and development of sporadic pancreatic adenocarcinoma, we have analyzed the expression of these genes by quantitative PCR and performed immunohistochemical analyses in normal pancreatic tissues, chronic pancreatitis, and pancreatic cancer specimens. RESULTS:BRCA1 expression was down-regulated in chronic alcoholic pancreatitis, in particular on the RNA level. Furthermore, our data indicate suppressed BRCA1 expression in pancreatic cancer on both the RNA and protein levels. Quantitative analysis of BRCA1 protein expression demonstrated regular staining in 50% of tumor specimens tested and reduced staining in 50% of tumor specimens tested. Correlation with the clinical outcome revealed a significantly better 1-year overall survival for patients with BRCA1-regular as compared with BRCA1-reduced or BRCA1-absent tumors. In contrast, no substantial differences in BRCA2 expression were found in chronic pancreatitis and pancreatic cancer samples. CONCLUSIONS: Our data demonstrate alteration of BRCA1 expression in chronic pancreatitis and sporadic pancreatic adenocarcinoma. We, for the first time, provide evidence for a role of BRCA1 in pancreatic carcinogenesis of noninherited tumors and for clinical outcome.
Authors: Natalia Bednarz; Elke Eltze; Axel Semjonow; Michael Rink; Antje Andreas; Lennart Mulder; Juliane Hannemann; Margit Fisch; Klaus Pantel; Heinz-Ulrich G Weier; Krzysztof P Bielawski; Burkhard Brandt Journal: Clin Cancer Res Date: 2010-06-30 Impact factor: 12.531
Authors: Hyo Jin Kang; Young Bin Hong; Hee Jeong Kim; Yong Weon Yi; Raghu G Nath; Young Soo Chang; Ho-Chan Cho; Insoo Bae Journal: Toxicol Lett Date: 2011-01-20 Impact factor: 4.372
Authors: Reena Shakya; Tamas Gonda; Michael Quante; Martha Salas; Samuel Kim; Jenna Brooks; Steffen Hirsch; Justine Davies; Angelica Cullo; Kenneth Olive; Timothy C Wang; Matthias Szabolcs; Benjamin Tycko; Thomas Ludwig Journal: Cancer Res Date: 2012-11-29 Impact factor: 12.701
Authors: Karina Vázquez-Arreguín; Jessica Maddox; Jinsuk Kang; Dongju Park; Reuben R Cano; Rachel E Factor; Thomas Ludwig; Dean Tantin Journal: Mol Cancer Res Date: 2018-01-12 Impact factor: 5.852
Authors: Rhonda M Jack; Meggie M G Grafton; Danika Rodrigues; Maria D Giraldez; Catherine Griffith; Robert Cieslak; Mina Zeinali; Chandan Kumar Sinha; Ebrahim Azizi; Max Wicha; Muneesh Tewari; Diane M Simeone; Sunitha Nagrath Journal: Adv Sci (Weinh) Date: 2016-04-18 Impact factor: 16.806
Authors: Adam Kowalewski; Łukasz Szylberg; Michał Saganek; Wojciech Napiontek; Paulina Antosik; Dariusz Grzanka Journal: J Cancer Res Clin Oncol Date: 2018-05-18 Impact factor: 4.553